Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease

International Journal of Neuroscience

Volumn 90, Issue 1-2, 1997, Pages 87-97

  Popović, Miroljub ^a,e   Popović, Natalija ^a   Jovanova Nešić, Katica ^a   Bokonjić, Dubravko ^b   Dobrić, Silva ^b   Kostić, Vladimir S ^c   Rosić, Nedeljko ^d  

^a Immunol Res Ctr Branislav J   (Macedonia)

^b Military Technical Institute

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY OF DEFENCE   (Serbia)

^e Immunology Research Center Belgrade   (Yugoslavia)

Author keywords

Alzheimer's disease; Nucleus basalis magnocellularis; Physostigmine; Rats; Two way active avoidance; Verapamil

Indexed keywords

EID: 0031171068     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459709000628     Document Type: Article

References (47)

1. Bartus, R. T., Dean, R. L., Beer, B & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction, Science. 217, 408-147.
2. Caltagirone, C., Gainotti, G. & Masullo, C. (1982). Oral administration of physostigmine does not improve cognitive or mnesic performance in Alzheimer's presenile dementia. International Journal of Neuroscience, 16, 247-249.
3. Cheng, B. & Mattson, M. P. (1992). Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bNGF, Experimental Neurology, 117, 114-123.
4. Coyle, J. T., Price, D. L. & DeLong, M. R. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation, Science, 19, 1184-1190.
5. Davis, K. L. & Mohs, R. C. (1982) Enhancement of memory with oral physostigmine in Alzheimer's disease, American Journal of Psychiatry, 139, 1421-1424.
6. Doble, A. (1995). Excitatory amino acid receptors and neurodegeneration. Therapie, 50, 319-337.
7. Dokla, C. P. J. & Thal, L. J. (1988). Effect of cholinesterase inhibitors on Morris water maze task behavior following lesions of nucleus basalis magnocellularis, Behavioral Neuroscience, 102, 861-871.
8. Farber, J. L. (1981). The role of calcium in cell death. Life Science, 29, 1289-1295.
9. Gibson, G E. & Peterson, C. (1987). Calcium and the aging nervous system. Neurobiology of Aging, 8, 329-343.
10. Grobe-Einsler, R (1993). Clinical aspects of nimodipine, Clinical Neuropharmacology, 16 (suppl. 1), S39-S45.
11. Haroutunian, V., Kanof, P. & Davis, K. L. (1985). Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sciences, 37, 945-952.
12. Hepler, D. J., Wenk, G. L., Cribbs, B. L., Olton, D S. & Coyle, T. (1985). Memory impairment following basal forebrain lesions. Brain Research, 346, 8-14
13. Hoschle, C. (1991). Do calcium antagonists have a place in the treatment of mood disorders? Drugs, 42, 721-729.
14. Ingram, D. K., Joseph, J. A., Spangler, E. L., Roberts, D., Hengemihle, J. & Fanelli, R. J. (1994). Chronic nimodipine treatment in aged rats: analysis of motor and cognitive effects and muscarinic-induced striatal dopamine release, Neurobiology of Aging, 15, 55-61.
15. Khachaturian, Z. S. (1989). The role of calcium regulation in brain aging: reexamination of a hypothesis, Aging, 1, 17-34.
16. 2+-dependent afterhyperpolarizations in hippocampal neurons in aged rats, Science, 226, 1089-1092.
17. Landfield, P. W. (1989). Calcium homeostasis in brain aging and Alzheimer's disease. In, Bergener M, Reisberg B, (eds), Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 276-287.
18. Lee, E. H. Y. & Lin, W. R. (1991). Nifedipine and verapamil block the memory facilitating effect of corticotropin-releasing factor in rats. Life Sciences, 48, 1333-1340.
19. Leslie, S. W., Chandler, L. J., Barr, E. M. & Farrar, R. P. (1983). Reduced calcium uptake by rat brain mitochondria and synaptosomes in response to aging, Brain Research, 329, 177-183.
20. LoConte, G., Bartolini, L., Casamenti, F, Marconcini-Pepeu, I. & Pepeu, G. (1982). Lesions of cholinergic forebrain nuclei: changes in avoidance behavior and scopolamine actions, Pharmacology, Biochemistry and Behavior, 17, 933-937.
21. 2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration, 4, 307-314.
22. Mandel, R. J. & Thal, L. J. (1988). Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats, Psychopharmacology, 96, 421-425.
23. Mandel, R. J., Chen, A D., Connor, D J. & Thal, L. J. (1989) Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers, Journal of Pharmacology and Experimental Therapeutics, 251, 612-619.
24. Mattson, M. P., Cheng, B , Davis, D., Bryant, K , Liederburg, I. & Rydel, R. E. (1992). β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience, 12, 376-389.
25. Mattson, M. P., Rydel, R. E., Lieberburg, I. & Smith-Swintosky, V. L. (1993). Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Annals of the New York Academy of Sciences, 679, 1-21.
26. 2+ regulation, Mechanisms of Aging and Development, 25, 215-225.
27. Miyamoto, M., Shintani, M., Nagaoka, A. & Nagawa, Y (1985). Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks, Brain Research, 328, 97-104.
28. Mohs, R C., Davis, B. M., Johns, C. A., Mathe, A. A., Greenwald, B. S., Horvath, T. B. & Davis, K. I. (1985). Oral physostigmine treatment of patients with Alzheimer' s disease, American Journal of Psychiatry, 142, 28-33.
29. Murray, C. L. & Fibiger, H. C. (1985). Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine, Neuroscience, 14, 1025-1032.
30. Nakamura, S., Tani, Y., Maezono, Y., Ishihara, T. & Ohno, T. (1992). Learning deficits after unilateral AF64A lesions in the rat basal forebrain: role of cholinergic and noncholinergic systems, Pharmacology, Biochemistry and Behavior, 42, 119-130.
31. Narang, P. K. & Cutler, N. R. (1986). Pharmacotherapy in Alzheimer's disease: Basis and rationale, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10, 519-531.
32. Nelson, S. R. & Foltz, F. M. (1983). Hypocalcemia and motor neuron degeneration in paraphysectionized frogs, Experimental Neurology, 79, 763-772.
33. Nyakas, C., Buwalda, B., Kramers, R. J., Traber, J & Luiten, P. G. (1994). Postnatal development of hippocampal and neocortical cholinergic and serotonergic innervation in rat: effects of nitriteinduced prenatal hypoxia and nimodipine treatment, Neuroscience, 59, 541-559.
34. Paxinos, G. & Watson, C. (1982). The rat brain in stereotaxic coordinates, Sydney: Academic Press, 1982.
35. Peterson, C. & Gibson, G. E (1983). Aging and 3,4-diaminopyridine alter synaptosomal calcium uptake, Journal of Biological Chemistry, 258, 11482-11486.
36. Peterson, C., Gibson, G. E. & Blass, J. P. (1985). Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease, New England Journal of Medicine, 312, 1063-1064.
37. Peterson, C. & Goldman, J. E. (1986). Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors, Proceedings of the National Academy of Sciences of the United States of America, 83, 758-762.
38. Peterson, C., Ratan, R. R., Shelanski, M L. & Goldman, J E. (1986). Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors, Proceedings of the National Academy of Sciences of the United States of America, 83, 7999-8001.
39. Popović, M., Jovanova-Nešić, K., Bokonjić, D , Dobrić, S., Popović, N. & Rosić, N. (1995). Effect of verapamil on spontaneous motor activity and two-way avoidance learning in nucleus basalislesioned rats, European Journal of Neuroscience, suppl 8, 171
40. Popović, M , Jovanova-Nešić, K., Popović, N., Bokonjić, D., Dobrić, S., Rosić, N. & Rakić, Lj. (1996). Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats, International Journal of Neuroscience, 86, 281-299.
41. Rosić, N. & Bignami, G. (1970). Depression of two-way avoidance learning and enhancement of passive avoidance learning by small doses of physostigmine, Neuropharmacology, 9, 311-316.
42. Santucci, A. C., Kanof, P. D. & Haroutunian, V. (1989). Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats, Psychopharmacology, 99, 70-74.
43. Sen, A. P., Boksa, P. &. Quirion, R. (1993). Brain calcium channel related dihydropyridine and phenylalkylamine bindings sites in Alzheimer's, Parkinson's and Huntington's diseases, Brain Research, 611, 216-221.
44. Simonić, A., Župan, G. & Domino, E. F. (1990). Effects of various cholinomimetic agents on passive avoidance behaviour in the nucleus basalis lesioned rats, Iugoslavica Physiologica et Pharmacologica Acta, 26, 267-274.
45. Thal, L. J., Fuld, P A., Masur, D. M. & Sharpless, N. S. (1983). Oral physostigmine and lecithin improve memory in Alzheimer disease, Annals of Neurology, 13, 491-496.
46. Thai, L. J., Dokla, C. P. J. & Armstrong, D. M. (1988). Nucleus basalis lesions: biochemical and immunocytochemical recovery and effect of cholinesterase inhibitors on passive avoidance. Behavioral Neuroscience. 102, 852-860.
47. Yamazaki, N., Kato, K., Kurihara, E. & Nagaoka, A. (1991). Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats, Psychopharmacology, 103, 215-222.